Trial Profile
A REAL-LIFE RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND IMPACT OF LONG-TERM TREATMENT WITH OMALIZUMAB WITH EMPHASIS ON MARKERS OF RESPONSE IN A CLINICAL PRACTICE IN APPROXIMATELY 240 PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Acronyms The REALITY
- 02 Aug 2019 Status changed to completed as per results published in the Annals of Allergy, Asthma and Immunology
- 02 Aug 2019 Results evaluating response to omalizumab therapy by a novel multi model approach (SMART) published in the Annals of Allergy, Asthma and Immunology
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society